Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Surveillance of Inhaled Iloprost in Pulmonary Hypertension
NCT00185315Phase 3Completed
- Sponsor
- Bayer
- Start
- Feb 2000
- Modality
- Orthosteric Ligands
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of iloprost in pulmonary hypertension (PH), sponsored by Bayer. Primary endpoint: Adverse events. Started Feb 2000; status: completed.
02
Drugs
iloprost
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT00185315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00185315.